Patriots' Cannon wins courage award

New England Patriots rookie offensive lineman Marcus Cannon has been named the winner of the team's Ed Block Courage Award. The recipient, decided by the team, is 'the player who best exemplifies the principles of courage and sportsmanship' and who also serves as an inspiration to his teammates.

The 6'6", 348lb rookie has certainly done that and more during his first year with the Patriots: Initially, his career was in jeopardy after he was diagnosed with B-cell non-Hodgkin's lymphoma. The Patriots drafted him anyway, and three months after finishing chemotherapy and radiotherapy treatment, Cannon hit the practice field with his teammates for the first time. Three weeks later, he saw his first bit of pro-football action, debuting in the fourth quarter of a nationally televised Monday Night game.

“[Marcus] did what he had to do, but at the same time he was always there for the team and was always doing what he could to help the team," said coach Bill Belichick. "I’m proud that he’s on our team and what he’s accomplished. He certainly deserves to be recognized for it."

Source: The Boston Globe

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap